FAM230A

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM230A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM230A data layer compared with 9 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher FAM230A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM230A expression acts as an unfavorable survival marker.

ESCA are the cancer types where FAM230A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
ESCAOSMedianII,III,IV0.2160.702.0146view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FAM230A–ESCA (OS)

Kaplan–Meier survival curve for FAM230A mutant vs wild-type samples in ESCA.

Open the ESCA breakdown →

Exploration